Background
Methods
Selection of interventions
Assumption
|
Justification
|
Impact or weight in the model
| |
---|---|---|---|
1 | Mild headache is not associated with disability | If the assumption were false, the cost-effectiveness of acute therapy would be slightly reduced | |
2 | The pain associated with untreated migraine is at least moderate | On the one hand, the diagnostic criteria for migraine describe the pain as at least moderate [11]; on the other hand, most clinical trials have recruited patients with at least moderate pain | None |
3 | In a stepped-care treatment paradigm, triptans are used only by non-responders to simple analgesics | This is the standard stepped-care paradigm, in which more expensive medications are reserved for those shown to need them | The alternative would be a multiplicity of scenarios of no obvious interest |
4 | Acute treatment is initiated at attack onset (commencement of pain phase) | The assumption was necessary to establish a time zero for purposes of effect calculation and was subject to further assumptions regarding patient adherence (see below) | To the extent that the assumption was false, effect and therefore cost-effectiveness would be reduced |
5 | Each acute medication is used once per attack | The assumption was necessary because of dependence on clinical trials data | Additional doses would increase cost, particularly in the case of triptans (mean number of triptan doses per attack was reported as 1.4-1.5 in the USA [12], but this may not be representative of the countries of interest) |
6 | The endpoint of sustained headache-relief is an all-or-nothing response | The assumption is in line with the standard definitions of pain relief and sustained pain freedom [13] | The consequence of the assumption was an underestimation of effectiveness |
7 | Prophylaxis is offered only to the proportion of people with ≥3 migraine attacks/month | As a recommendation based on frequency only, this was conservatively chosen [6] | This is a clinical rather than an economic threshold, so it would be of limited interest to vary it. Lowering the threshold to ≥2 would increase the use of prophylactics with less gain per user |
8 | ASA has high current coverage (80%) in all study contexts except Zambia (50%) | This was conservative; ASA is available almost universally, but not easily in rural Zambia | No impact on cost-effectiveness estimations. Higher coverage would allow greater population health gain |
9 | As a result of non-adherence, a proportion of patients use OTC-drugs later than is ideal, and in suboptimal doses (described in the text). | Best estimate, formed from our clinical judgement | Better adherence would lead to higher health gain and therefore improve cost-effectiveness |
10 | Provider adherence is 75% | Best estimate, based on our experience | Higher adherence would allow greater population health gain, which would improve cost-effectiveness estimations |
11 | Public education improves adherence by 50% of the current deficit | Based on what can be in expected in real world settings | A greater improvement of consumer adherence would lead to improved cost-effectiveness as well as greater population health gain |
12 | Three-monthly doctor visits, each of 10 minutes’ duration, are needed for monitoring and prescription of triptans and prophylactics | Reflects typical clinical need and treatment practice in these countries | More or longer visits would increase costs |
13 | For consumer education, the number of leaflets needed is 50% of the disease prevalence, and one poster is required per 2,000 of the population | Leaflet numbers allows for high circulation/exposure; poster numbers conform to WHO programme costing standards | Increasing or decreasing leaflet or poster numbers would have a negligible impact on base-line results because the base-line cost of consumer education is very low (US$ 0.01-0.02 per capita) |
14 | For provider education, one physician per primary health-care centre per year will be trained for one day | This represents an effective approach to reaching primary health care throughout the country | Increasing or decreasing the number of trained providers would have a negligible impact on base-line results because the base-line cost of provider education is very low (US$ 0.01-0.02 per capita) |
Analytical model
Epidemiological data
Epidemiological variable
|
Sub-group
|
China
|
India
|
Russian Federation
|
Zambia
|
---|---|---|---|---|---|
Migraine prevalence (18–65 years) |
Male
| 5.4% | 19.4% | 12.6% | 18.0% |
Female
| 12.6% | 32.8% | 30.4% | 27.1% | |
Case distribution (attacks per month) |
Low frequency [<3]
| 62% | 63% | 52% | 50% |
High frequency [≥3]
| 38% | 37% | 48% | 50% | |
Mean attacks (per month) |
Low frequency
| 1.05 | 1.05 | 1.2 | 0.56 |
High frequency
| 5.65 | 4.59 | 6.4 | 3.94 | |
Mean duration of attack (hours) |
All cases
| 23.4 | 13.1 | 15.0 | 36.4 |
Time spent in ictal state (per year) |
Low frequency
| 3.4% | 1.9% | 2.5% | 2.8% |
High frequency
| 18.1% | 8.2% | 13.2% | 19.7% |
Estimation of intervention effectiveness
Intervention
|
Efficacy
|
Coverage
|
Provider adherence
|
Patient adherence
| |||
---|---|---|---|---|---|---|---|
Current
|
Target
|
Current
|
Target
|
Current
|
Target
| ||
Drugs providing sustained headache relief
| |||||||
ASA 1,000 mg | 39% [21] | 80% | 90% | 100% | 100% | 80% | 90% |
(Zambia 50%) | |||||||
Sumatriptan 50 mg | 35% [19] | 2% | (Zambia 80%) | 75% | 88% | 56% | 78% |
(Zambia 1%) | |||||||
Almotriptan 12.5 mg | 45% [20] | 0% | 75% | 88% | 56% | 78% | |
Drugs averting migraine attacks
| |||||||
Propranolol 160 mg | 28% [22] | 3% | 30% | 75% | 88% | 71% | 86% |
Topiramate 100 mg | 40% [23] | 1% | 75% | 88% | 60% | 80% | |
Amitriptyline 100 mg | 44% [24] | 3% | 75% | 88% | 42% | 71% |
Estimation of costs
Drug
|
Dose
|
Source
|
China
|
India
|
Russia
|
Zambia
|
---|---|---|---|---|---|---|
ASA
| 500 mg | International drug price indicator guide | $ 0.004 | $ 0.004 | $ 0.004 | $ 0.004 |
Propranolol
| 160 mg | $ 0.005 | $ 0.005 | $ 0.005 | $ 0.005 | |
Amitriptyline
| 100 mg | $ 0.006 | $ 0.006 | $ 0.006 | $ 0.006 | |
Topiramate
| 100 mg | $ 0.13 | $ 0.03 | $ 0.12 | $ 0.133 | |
Sumatriptan
| 50 mg | IMS database | $ 0.81 | $ 0.11 | $ 1.07 | $ 0.66 |
Almotriptan
| 12.5 mg | $ 5.19 | $ 5.19 | $ 5.19 | $ 5.19 |
Results
China
|
India
|
Russian Federation
|
Zambia
| ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Target coverage*
|
Healthy life years gained per year (per 1 m popn)
|
Cost per year per capita (US$)
|
Cost per healthy life year gained (US$)
|
ICER (US$)
|
Healthy life years gained per year (per 1 m popn)
|
Cost per year per capita (US$)
|
Cost per healthy life year gained (US$)
|
ICER (US$)
|
Healthy life years gained per year (per 1 m popn)
|
Cost per year per capita (US$)
|
Cost per healthy life year gained (US$)
|
ICER (US$)
|
Healthy life years gained per year (per 1 m popn)
|
Cost per year per capita (US$)
|
Cost per healthy life year gained (US$)
|
ICER (US$)
| |||||||||||||
A. ACUTE MANAGEMENT (NON-SPECIFIC DRUGS) | |||||||||||||||||||||||||||||
Simple analgesics (e.g. ASA 1 g)
| 90% | 530 | $ | 0.02 | $ | 34 | $ | 35 | 673 | $ | 0.05 | $ | 73 | $ | 75 | 1223 | $ | 0.07 | $ | 53 | $ | 63 | 1244 | $ | 0.03 | $ | 24 | $ | 24 |
With consumer education | 597 | $ | 0.03 | $ | 53 | $ | 204 | 757 | $ | 0.06 | $ | 77 | $ | 105 | 1376 | $ | 0.19 | $ | 136 | $ | 801 | 1400 | $ | 0.12 | $ | 85 | $ | 575 | |
B. ACUTE MANAGEMENT (SPECIFIC DRUGS) | |||||||||||||||||||||||||||||
Sumatriptan (50 mg)
| 90% | 152 | $ | 2.14 | $ | 14,061 | 193 | $ | 1.20 | $ | 6,201 | 352 | $ | 12.55 | $ | 35,684 | 358 | $ | 2.62 | $ | 7,330 | ||||||||
With consumer education | 212 | $ | 2.16 | $ | 10,159 | 269 | $ | 1.21 | $ | 4,485 | 490 | $ | 12.67 | $ | 25,869 | 498 | $ | 2.71 | $ | 5,442 | |||||||||
With provider training | 178 | $ | 2.16 | $ | 12,129 | 226 | $ | 1.20 | $ | 5,335 | 410 | $ | 12.64 | $ | 30,804 | 417 | $ | 2.64 | $ | 6,329 | |||||||||
With consumer education and provider training | 248 | $ | 2.17 | $ | 8,762 | 314 | $ | 1.21 | $ | 3,859 | 571 | $ | 12.76 | $ | 22,330 | 581 | $ | 2.73 | $ | 4,698 | |||||||||
Almotriptan (12.5 mg)
| 90% | 196 | $ | 5.59 | $ | 28,546 | 249 | $ | 14.55 | $ | 58,533 | 452 | $ | 23.38 | $ | 51,728 | 460 | $ | 8.82 | $ | 19,187 | ||||||||
With consumer education | 273 | $ | 5.61 | $ | 20,544 | 346 | $ | 14.56 | $ | 42,049 | 630 | $ | 23.51 | $ | 37,332 | 640 | $ | 8.91 | $ | 13,915 | |||||||||
With provider training | 229 | $ | 5.61 | $ | 24,528 | 290 | $ | 14.56 | $ | 50,187 | 527 | $ | 23.47 | $ | 44,508 | 536 | $ | 8.84 | $ | 16,482 | |||||||||
With consumer education and provider training | 318 | $ | 5.62 | $ | 17,652 | 404 | $ | 14.56 | $ | 36,053 | 735 | $ | 23.60 | $ | 32,121 | 747 | $ | 8.93 | $ | 11,953 | |||||||||
C. ACUTE STEPPED CARE MANAGEMENT | |||||||||||||||||||||||||||||
ASA (1 g) + sumatriptan (50 mg)
| 90% | 431 | $ | 2.52 | $ | 5,840 | 547 | $ | 1.62 | $ | 2,964 | 994 | $ | 15.71 | $ | 15,811 | 1011 | $ | 2.95 | $ | 2,917 | ||||||||
With consumer education | 600 | $ | 2.53 | $ | 4,215 | 761 | $ | 1.63 | $ | 2,139 | 1384 | $ | 15.84 | $ | 11,440 | 1408 | $ | 3.04 | $ | 2,158 | |||||||||
With provider training | 503 | $ | 2.53 | $ | 5,033 | 638 | $ | 1.62 | $ | 2,548 | 1160 | $ | 15.80 | $ | 13,630 | 1179 | $ | 2.97 | $ | 2,517 | |||||||||
With consumer education and provider training | 700 | $ | 2.54 | $ | 3,633 | $ | 24,271 | 888 | $ | 1.63 | $ | 1,839 | $ | 11,996 | 1615 | $ | 15.93 | $ | 9,861 | $ | 65,920 | 1643 | $ | 3.06 | $ | 1,861 | $ | 12,102 | |
D. PROPHYLAXIS + ACUTE MANAGEMENT | |||||||||||||||||||||||||||||
ASA (1 g) + amitriptyline (100 mg)
| 30% | 112 | $ | 0.18 | $ | 1,649 | 145 | $ | 0.26 | $ | 1,795 | 275 | $ | 1.45 | $ | 5,264 | 305 | $ | 0.24 | $ | 773 | ||||||||
With consumer education | 189 | $ | 0.20 | $ | 1,047 | 245 | $ | 0.27 | $ | 1,098 | 465 | $ | 1.57 | $ | 3,377 | 515 | $ | 0.32 | $ | 631 | |||||||||
With provider training | 130 | $ | 0.20 | $ | 1,517 | 169 | $ | 0.26 | $ | 1,565 | 321 | $ | 1.54 | $ | 4,790 | 355 | $ | 0.25 | $ | 716 | |||||||||
With consumer education and provider training | 220 | $ | 0.21 | $ | 959 | 286 | $ | 0.27 | $ | 957 | 543 | $ | 1.66 | $ | 3,059 | 601 | $ | 0.34 | $ | 573 | |||||||||
Sumatriptan (50 mg) + amitriptyline (100 mg)
| 30% | 49 | $ | 0.73 | $ | 14,872 | 63 | $ | 0.53 | $ | 8,329 | 121 | $ | 3.95 | $ | 32,633 | 134 | $ | 1.09 | $ | 8,102 | ||||||||
With consumer education | 83 | $ | 0.74 | $ | 8,962 | 107 | $ | 0.54 | $ | 5,010 | 205 | $ | 4.07 | $ | 19,902 | 227 | $ | 1.18 | $ | 5,188 | |||||||||
With provider training | 68 | $ | 0.74 | $ | 10,908 | 88 | $ | 0.53 | $ | 6,049 | 168 | $ | 4.04 | $ | 24,027 | 186 | $ | 1.11 | $ | 5,937 | |||||||||
With consumer education and provider training | 115 | $ | 0.76 | $ | 6,571 | 149 | $ | 0.54 | $ | 3,637 | 284 | $ | 4.16 | $ | 14,644 | 315 | $ | 1.19 | $ | 3,796 | |||||||||
ASA + sumatriptan + amitriptyline
| 30% | 103 | $ | 0.80 | $ | 7,740 | 133 | $ | 0.73 | $ | 5,467 | 248 | $ | 4.55 | $ | 18,319 | 275 | $ | 1.20 | $ | 4,362 | ||||||||
With consumer education | 174 | $ | 0.81 | $ | 4,657 | 226 | $ | 0.74 | $ | 3,273 | 420 | $ | 4.67 | $ | 11,128 | 465 | $ | 1.29 | $ | 2,773 | |||||||||
With provider training | 143 | $ | 0.81 | $ | 5,668 | 185 | $ | 0.73 | $ | 3,961 | 345 | $ | 4.64 | $ | 13,449 | 382 | $ | 1.22 | $ | 3,191 | |||||||||
With consumer education and provider training | 241 | $ | 0.82 | $ | 3,409 | 313 | $ | 0.74 | $ | 2,371 | 583 | $ | 4.76 | $ | 8,166 | 645 | $ | 1.31 | $ | 2,026 |